Clinical Trials
Paul Hudson has acknowledged the firm’s R&D setbacks but says they are par for the course when tackling science ‘that has never been done before.’
Attention now shifts to the company’s review of unblinded data and whether changes to patient enrolment could support further evaluation.
Boehringer Ingelheim hopes TPRC6 inhibition can provide a disease-modifying therapy for focal segmental glomerulosclerosis, which has no approved therapy. The smallest dose used in its Phase II study showed the highest response rate.
The Swiss company’s strategy head, Ronny Gal, joins calls for improvement in US competitiveness, as McKinsey highlights competition from other Asian countries beyond China.
Multiple Chinese biotechs are seeking to raise new funds through IPOs on the Hong Kong and Beijing stock exchanges to support international clinical trials for their first-in-class molecules.
The company announced Phase II data and plans for its registrational Phase III trial as CEO Mark Erlander and chief financial officer James Levine left the company.
Roche's CT-388 shows promise in Phase II obesity trial but analysts question "commercial relevance" in a crowded market.
Fund IV exclusively targets company creation and early-stage investing across the UK and the US.
The Phase I/II study’s trial page was updated to say it was no longer recruiting patients after recruiting only 23 of the originally planned 260.
The company said amorphous rifaximin solid soluble dispersion did not meet the primary endpoint in two Phase III RED-C trials in the prevention of hepatic encephalopathy in patients with cirrhosis.
The Paris-headquartered giant has heralded data from two new Phase III trials of the anti-OX40L antibody but there are still concerns over its level of efficacy.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
The company announced that the Phase III ROSELLA trial in platinum-resistant ovarian cancer met its overall survival primary endpoint.
The US biotech has upsized its public offering to $175m after the success of soquelitinib in a very early trial for atopic dermatitis.
While a record number of China-originated first-in-class drugs were approved domestically in 2025, only one has so far entered clinical development overseas with its originator as the sole sponsor. But more progress is expected this year.
The company plans to take Aqneursa to regulators in the US, Europe and elsewhere for ataxia-telangiectasia (A-T), which currently lacks any approved therapy.
The inflammatory skin disease typically affects the anogenital area and the Denmark-headquartered firm has started a Phase III trial evaluating its chronic hand eczema in that space.
HUTCHMED sees good potential for its Syk inhibitor in autoimmune setting following positive topline Phase III results, with China NDA planned in first half.
The Phase II data for intismeran autogene in melanoma were mostly incremental, but the program’s continued success is a cornerstone of Moderna’s breakeven strategy.
The US giant is narrowing its focus on obesity and cancer.